Clinical Significance of Expression and Amplification of the DcR3 Gene in Pancreatic Carcinomas

Zhou, Jian; Song, Shiduo; Li, Dechun; Zhou, Jin; Zhu, Dongming; Zheng, Shaojiang

doi:10.7314/apjcp.2012.13.2.719

Cited by 8 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our previous study, we demonstrated that the expression of DcR3 was associated with clinicopathological features, such as lymph node metastasis, tumor size and clinical stage (16). In this study, we also found that silencing DcR3 expression enhanced the apoptotic effects mediated by FasL in vitro and inhibited the tumor growth in vivo.…”

Section: Discussionsupporting

confidence: 67%

Silencing of decoy receptor 3 (DcR3) expression by siRNA in pancreatic carcinoma cells induces Fas ligand-mediated apoptosis in vitro and in vivo

Zhou

Song

et al. 2013

International Journal of Molecular Medicine

Self Cite

View full text Add to dashboard Cite

Abstract. Decoy receptor 3 (DcR3) is abundantly expressed in human tumors and protects cells from a wide range of apoptotic stimuli. In this study, we demonstrate that DcR3 is overexpressed in pancreatic carcinoma cells, and that the pancreatic carcinoma cell lines, Panc-1 and SW1990, are resistant to Fas ligand (FasL)-mediated apoptosis. To further define the function of DcR3 in cell growth and apoptosis, we used small interfering RNA (siRNA) to knockdown the expression of the DcR3 gene in Panc-1 and SW1990 cells. Our results revealed that the silencing of DcR3 expression enhanced the inhibitory effects of FasL and reduced the capabiltiy of the cells for proliferation and colony formation in vitro. In addition, the downregulation of DcR3 modulated the cell apoptotic regulators, Fas-associated death domain (FADD), caspase-3 and caspase-8, thus triggering cell apoptosis. Furthermore, the knockdown of DcR3 inhibited the growth of Panc-1 tumor xenografts. Taken together, our findings indicate that DcR3 is important in cancer progression and may be a used as a potential therapeutic target for the gene therapy of pancreatic carcinoma.

show abstract

Section: Discussionsupporting

confidence: 67%

Silencing of decoy receptor 3 (DcR3) expression by siRNA in pancreatic carcinoma cells induces Fas ligand-mediated apoptosis in vitro and in vivo

Zhou

Song

et al. 2013

International Journal of Molecular Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…Pancreatic carcinoma is one of the most malignant tumors of alimentary system (Hua et al, 2009;Zhou et al, 2012). The majority of pancreatic carcinoma are in an advanced stage at the time of diagnosis, as early diagnosis of pancreatic carcinoma is still difficult (Ikeda et al, 2009).…”

Section: Discussionmentioning

confidence: 99%

“…Pancreatic carcinoma is one of the most malignant tumors of alimentary system,and its incidence rate had a tendency to rise in the past decades (Hua et al, 2009;Tuli et al, 2012;Zhou et al, 2012). Early diagnosis of pancreatic carcinoma is still difficult, the majority patients with pancreatic carcinoma are in an advanced stage at the time of diagnosis (Ikeda et al,2009;Klauss et al, 2012;Zhou et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Continuous Transarterial Infusion Chemotherapy with Gemcitabine and 5-Fluorouracil for Advanced Pancreatic Carcinoma

Hong

Zhou²,

Sun³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The objective effective rate in transarterial group was 33.3% versus 25% in the systemic group, the difference not being significant (P=0.626). Clinical benefit rates(CBR) in the transarterial and systemic groups were 83.3% and 58.3%, respectively (P=0.014). The means and medians for survival time in transarterial group were higher than those of the systemic group (P < 0.005). at the same time, the adverse effects did not significantly differ between the two groups (P > 0.05). Conclusion: Continuous transarterial infusion chemotherapy with gemcitabine and 5-fluorouracil could improve clinical benefit rate and survival time of patients with advanced pancreatic carcinoma, compared with systemic venous chemotherapy. Since adverse effects were limited in the transarterial group, the regimen of continuous transarterial infusion chemotherapy can be used more extensively in clinical practice. A CT and MRI conventional sequence can be used for efficacy evaluation after chemotherapy in pancreatic carcinoma.

show abstract

“…It is one of the most lethal cancers among malignant diseases with a 5-year survival rate of about 5%,1 and its incidence rate has increased in the past 4 decades 2. Early diagnosis of pancreatic carcinoma is still difficult, and the majority of patients are diagnosed in an advanced stage 2–4…”

Section: Introductionmentioning

confidence: 99%

Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma

Gong

Zhang²,

Min³

et al. 2013

CIA

View full text Add to dashboard Cite

BackgroundPancreatic carcinoma possesses one of the highest lethality rates, highest drug-resistance, and highest incidence rates. The objective of this research was to enhance the efficacy and drug-resistance for pancreatic carcinoma by using inhibition of SIRT1 combined with gemcitabine therapy methods.MethodsThree pancreatic carcinoma cells (PANC-1 cells, BxPC-3 cells, and SW1990 cells) received treatment with physiological saline, inhibition of SIRT1, gemcitabine, and combination therapy with inhibition of SIRT1 and gemcitabine in vitro; then BxPC-3 pancreatic cancer xenogeneic mice also received treatment with physiological saline, inhibition of SIRT1, gemcitabine, and combination therapy with inhibition of SIRT1 and gemcitabine in vivo.ResultsThe cleaved poly ADP ribose polymerase (PARP)-1 effect of drug in pancreatic carcinoma cells was significantly different (P < 0.05) and the efficacy in descending order was the combination therapy with inhibition of SIRT1 and gemcitabine, inhibition of SIRT1, and gemcitabine. The BxPC-3 pancreatic cancer xenogeneic mice model received treatment with physiological saline, inhibition of SIRT1, gemcitabine, and combination therapy with inhibition of SIRT1 and gemcitabine in vivo and the results showed that the tumor volumes decreased and the survival rate within 45 days increased according to the order of the given drugs and the difference was significant (P < 0.05).ConclusionCombination therapy with inhibition of SIRT1 and gemcitabine could improve efficacy and survival time in a BxPC-3 pancreatic cancer xenogeneic mice model, compared with single inhibition of SIRT1, or single gemcitabine therapy. The combination therapy method is a potential treatment method for pancreatic carcinoma.

show abstract

Clinical Significance of Expression and Amplification of the DcR3 Gene in Pancreatic Carcinomas

Cited by 8 publications

References 22 publications

Silencing of decoy receptor 3 (DcR3) expression by siRNA in pancreatic carcinoma cells induces Fas ligand-mediated apoptosis in vitro and in vivo

Silencing of decoy receptor 3 (DcR3) expression by siRNA in pancreatic carcinoma cells induces Fas ligand-mediated apoptosis in vitro and in vivo

Continuous Transarterial Infusion Chemotherapy with Gemcitabine and 5-Fluorouracil for Advanced Pancreatic Carcinoma

Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma

Contact Info

Product

Resources

About